Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern cooperative oncology group study E1992

Leukemia

Volumn 12, Issue 7, 1998, Pages 1037-1040

  Dutcher, J P ^a,e   Lee, S ^b   Paietta, E ^a   Bennett, J M ^c   Stewart, J A ^d   Wiernik, P H ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Blast crisis; Carboplatin; Chronic myeloid leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MALE; METABOLIC DISORDER; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REMISSION; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 0031875109     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401056     Document Type: Article

References (13)

1. Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH. Treatment of blast crisis of chronic myelogenous leukemia with 5-azacytidine and VP-16-213. Cancer Treat Rep 1982; 66: 267-271.
2. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of blastic phase of chronic myelogenous leukemia with mitoxantrone and highdose cytosine arabinoside. Cancer 1988; 62: 672-676.
3. Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, Cassileth PA. Phase II study of mitoxantrone and 5-azacytidine for accelerated or blast crisis of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6: 770-775.
4. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolies CJ. Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 707-717.
5. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, Devore III RF. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14: 2054-2060.
6. Lee EJ, Egorin M, VanEcho DA, Cohen AE, Tait N, Schiffer CA. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J Natl Cancer Inst 1988; 80: 131-135.
7. Meyers F, Welborn J, Lewis J, Flynn N. Infusion carboplatin in relapsed acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 173-178.
8. Vogler R, Harrington DP, Winton EF, Lazarus HM, Bennett JM, Cassileth PA, Oken MM. Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia 1992; 6: 1072-1075.
9. Simon R. Optimal two-stage designs for phase II clinical studies. Controlled Clinical Trials 1989; 10: 1-10.
10. Bishop YMM, Fienberg SE, Holland PW. Discrete Multivariate Analysis, Theory and Practice. MIT Press: Cambridge, MA, 1975.
11. Kaplan EL, Meier R. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50: 163-170.
13. Dutcher JP, Wiernik PH. Pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. Proc Am Soc Clin Oncol 1998 (in press).